Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Aging alters social preferences through distinct brain mechanisms

2

Feb 2026

Aging alters social preferences through distinct brain mechanisms

The loss of social connectedness as people age increases the odds of cognitive-related disorders and can worsen health outcomes in older populations. But is there a direct relationship between social behavior and cognition? Subhadeep Dutta Gupta, Peter Rapp, and colleagues, from the National Institute on Aging, developed a rat model to probe social cognition in the aging brain.

Hopeful climate engagement may reduce mental health distress

2

Feb 2026

Hopeful climate engagement may reduce mental health distress

Climate worry is associated with depressive and anxiety symptoms among Finns of all ages. However, these symptoms are less common among individuals whose climate-related hope is combined with various forms of action, such as volunteering, following a plant‑based diet or avoiding air travel.

Most commercially insured patients live with chronic conditions

2

Feb 2026

Most commercially insured patients live with chronic conditions

The majority (57.5 percent) of commercially insured patients had at least one chronic condition in 2024. The average allowed amount for a patient with no chronic conditions was $1,590, while the average allowed amount for a patient with one chronic condition was nearly double ($3,039).

Diabetes drug use linked to fewer gout treatments

2

Feb 2026

Diabetes drug use linked to fewer gout treatments

Natalie McCormick, PhD, of the Rheumatology and Allergy Clinical Epidemiology Research (RACER) Center within the Division of Rheumatology in the Mass General Brigham Department of Medicine, is the lead author of a paper published in Diabetes Care, "Gout-Related Medication Use After Initiating Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Gout and Type 2 Diabetes: Population-Based Target Trial Emulation Studies."

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.